FDA Warning Letter to ZOLL Medical Corporation (2026-04-30) — CGMP/QSR/Medical Devices/Adulterated
Letter issued · posted to fda.gov .
Subject as published: CGMP/QSR/Medical Devices/Adulterated
TL;DR
The short version: FDA issued a Warning Letter to ZOLL Medical Corporation on 2026-04-30 citing: CGMP/QSR/Medical Devices/Adulterated. Full letter: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/zoll-medical-corporation-711320-04302026
Argus analysis
ZOLL Medical Corporation (MARCS-CMS 711320) received an FDA Warning Letter dated April 30, 2026 from the Center for Devices and Radiological Health. The letter cites: CGMP/QSR/Medical Devices/Adulterated. FDA posts Warning Letters to fda.gov after an internal review period; this one was made public on June 16, 2026.
CGMP citations typically reference 21 CFR Part 211 (finished pharmaceuticals) or Part 111 (dietary supplements), covering subjects such as identity testing of incoming components, validated cleaning procedures, batch-failure investigations, and stability program design. Repeat or systemic findings are what typically drive FDA toward import alert or consent decree escalation.
FDA Warning Letters typically specify a 15-working-day response window for the recipient to detail corrective actions. Compliance teams at peer companies in the same CGMP (Current Good Manufacturing Practice) category commonly use a newly published letter as a prompt to re-check their own procedures against the same citation, and to watch fda.gov for a close-out letter confirming the cited firm's corrective action was accepted — or, absent one, for escalation to import alert, injunction, or product seizure.
Severity context
High severity. Typically QSR / device CGMP, adulterated-drug, or significant labeling matters — usually drives a documented corrective and preventive action (CAPA) program.
Regulatory background
CGMP citations typically reference 21 CFR Part 211 (drugs) or 21 CFR Part 600 (biologics). Common subjects include identity testing of incoming components (211.84), validated cleaning procedures (211.67), and stability program design (211.166).
What peer compliance teams typically do next
Most compliance officers at peer companies use a Warning Letter against a named entity as a checklist for their own CAPA program. Common steps: pull the verbatim FDA letter; map each cited 21 CFR section against the team’s SOP library; confirm CAPA coverage; brief the QMR (Quality Management Review) on whether the cited subject matter is in scope for the next internal audit. The 15-business-day response window applies to the cited entity, not to peers — but a documented internal review against the cited subjects is what regulators expect to see if a peer is later inspected on the same topic.
Excerpt from the FDA Warning Letter (public domain, 17 USC §105)
WARNING LETTER ZOLL Medical Corporation MARCS-CMS 711320 — April 30, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: VIA Electronic Mail Product: Medical Devices Recipient: ZOLL Medical Corporation 269 Mill Road Chelmsford , ME 01824 United States jrennert@zoll.com Issuing Office: Center for Devices and Radiological Health United States WARNING LETTER CMS # 711320 April 30, 2026 Dear Mr. Rennert: During an inspection of your firm located in Chelmsford, MA from February 27, 2025 through April 15, 2025, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures X Series/Advanced automated external defibrillators (AEDs) (Class 3), Zoll MRI Compatible 731 Ventilators (Class 2), OneStep electrodes (Class 3), and Accuvent Sensors (Class 3). Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body. Quality System Regulation Violations This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We received responses from Paul Dias, Vice President of Service, Quality and Regulatory Affairs, dated May 6, 2025, from Brian Abbott, Principal Quality Assurance Compliance Engineer, dated June 8, 2025 and July 8, 2025, September 8, 2025, October 8, 2025, November 7, 2025, December 8, 2025, January 10, 2026, February 6, 2026, March 6, 2026, April 6, 2026 and from Jill McFadden, Principal Quality Assurance Compliance Engineer, dated August 8, 2025, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm on April 15, 2025. We address these responses below, in relation to each of the noted violations. These violations include, but are not limited to, the following: 1) Failure to establish and maintain procedures for implementing corrective and preventive action, as required by 21 CFR 820.100(a). Specifically, your firm did not adequately establish your “Corrective and Preventive Action Procedure,” 5004-0002-RP, Revision W. For example: A. Your firm failed to identify the action(s) needed to correct and prevent recurrence of nonconforming product and other quality problems, as required by 21 CFR 820.100(a)(3). Specifically, your firm did not follow your Corrective and Preventive Action (CAPA) Procedure, 5004-0002-RP, section 7.3 which states “Quality Assura…
Excerpt only. The full verbatim Warning Letter is the source of truth — always read the original before regulatory decisions.
The verbatim FDA Warning Letter is the source of truth. Always read the original before acting on any analysis or summary on this page.
Read the full letter on fda.gov ↗Frequently asked questions
- What FDA violations was ZOLL Medical Corporation cited for?
- The FDA Warning Letter to ZOLL Medical Corporation (issuing office: Center for Devices and Radiological Health) cites: CGMP/QSR/Medical Devices/Adulterated. Classification: CGMP — Current Good Manufacturing Practice.
- When did FDA issue the warning letter to ZOLL Medical Corporation?
- FDA issued the letter (MARCS-CMS 711320) on 2026-04-30 and posted it publicly on fda.gov on 2026-06-16.
- Is the FDA warning letter to ZOLL Medical Corporation publicly available?
- Yes. The full verbatim letter is published at fda.gov. Argus HQ links directly to the source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/zoll-medical-corporation-711320-04302026.
- What does a "high" severity rating mean for this letter?
- High severity. Typically QSR / device CGMP, adulterated-drug, or significant labeling matters — usually drives a documented corrective and preventive action (CAPA) program.
argus.hq
Don’t find out about the next one six weeks late.
Argus reads every FDA Warning Letter the day it publishes, summarizes it against your watchlist, and lands the ones touching your business in your inbox at 6am ET. $199/month. Cancel any time.
methodology
The analysis above is produced by Anthropic Claude Haiku 4.5 against the verbatim FDA Warning Letter excerpt and is brand-voice lint-checked before publish. The TL;DR is the same summary that ships in the customer email digest. Severity is auto-classified by Argus from the subject string and letter body using rules documented in lib/ingestion/fda-warning-letters.ts.
Argus HQ is informational only. Summaries and analyses are AI-generated and may contain errors, misclassifications, or omissions. Verify against the FDA source URL above. Argus HQ is not a law firm, accounting firm, or regulatory agency, and provides no legal, accounting, financial, medical, or regulatory advice.
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). FDA Warning Letter to ZOLL Medical Corporation (2026-04-30) — CGMP/QSR/Medical Devices/Adulterated. Digital Empire LLC. Retrieved from https://argushq.ai/fda/warning-letter/fda-wl-zoll-medical-corporation-2026-04-30-cgmp
"FDA Warning Letter to ZOLL Medical Corporation (2026-04-30) — CGMP/QSR/Medical Devices/Adulterated." Argus HQ Research, Digital Empire LLC, 2026, argushq.ai/fda/warning-letter/fda-wl-zoll-medical-corporation-2026-04-30-cgmp.
Argus HQ Research. "FDA Warning Letter to ZOLL Medical Corporation (2026-04-30) — CGMP/QSR/Medical Devices/Adulterated." Digital Empire LLC. Accessed July 13, 2026. https://argushq.ai/fda/warning-letter/fda-wl-zoll-medical-corporation-2026-04-30-cgmp.
@misc{argushq_argushq_ai_fda_warning_letter_fda_wl_zoll_medical_corporation_2026_04_30_cgmp_2026,
title = {FDA Warning Letter to ZOLL Medical Corporation (2026-04-30) — CGMP/QSR/Medical Devices/Adulterated},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire LLC},
url = {https://argushq.ai/fda/warning-letter/fda-wl-zoll-medical-corporation-2026-04-30-cgmp},
note = {Accessed: July 13, 2026}
}